Key Differences When Switching From Wegovy To Mounjaro
Understanding The Switch From Wegovy To Mounjaro: Mechanism Differences
The primary consideration when evaluating a switch from Wegovy to Mounjaro lies in their distinct mechanisms of action, both designed to support weight management alongside a reduced-calorie diet and increased physical activity. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics a single natural fullness hormone, whilst Mounjaro contains tirzepatide, a dual agonist targeting both GIP and GLP-1 receptors. This dual-hormone approach represents a different therapeutic strategy that some patients and prescribers may consider when current treatment isn't providing optimal results or tolerability.
Both prescription-only medicines require careful clinical assessment before switching, as the transition involves different dosing schedules and potential side effect profiles. Wegovy follows a 5-dose escalation from 0.25mg to 2.4mg maintenance over 16 weeks, whilst Mounjaro utilises 6 doses escalating from 2.5mg to 15mg over 20 weeks. Your prescriber will evaluate your current response, any side effects experienced, and individual health factors to determine whether switching from Wegovy to Mounjaro aligns with your weight management goals. The decision requires professional medical guidance rather than patient-directed changes.
Pricing Comparison For Switch From Wegovy To Mounjaro Treatment Options
EverydayMeds offers transparent pricing for both treatments, allowing patients and prescribers to consider cost factors when evaluating a switch from Wegovy to Mounjaro. Wegovy single pens range from £79.99 for the 0.25mg starter dose to £209.99 for the 2.4mg maintenance dose, with new customers applying code FIRST40 at checkout. Mounjaro pricing follows a different structure, with maintenance doses typically positioned at different price points reflecting the distinct dosing requirements and manufacturing considerations.
Bundle options provide convenience for both treatments, with Wegovy's Intro Trio (0.25mg, 0.5mg, 1mg) available for £299.99 and the Ultimate Stability Trio offering three months of 2.4mg maintenance for £649.99. When considering a switch from Wegovy to Mounjaro, patients often evaluate the total treatment cost over their expected duration of therapy. Returning customers benefit from code DOSE25 for ongoing prescriptions, whilst our clinical team can advise on the most cost-effective approach based on your prescribed treatment plan.
Clinical Evidence Supporting Switch From Wegovy To Mounjaro Decisions
The decision to switch from Wegovy to Mounjaro should be informed by understanding each treatment's clinical evidence base, though direct head-to-head comparisons aren't available due to different trial designs and populations. Wegovy's efficacy was demonstrated in the STEP trial programme, with STEP 1 showing approximately 15% average weight loss at 68 weeks when used alongside diet and exercise (Wilding et al., NEJM, 2021). These results established semaglutide's role in weight management for eligible patients.
Mounjaro's clinical evidence comes from the SURMOUNT trials, demonstrating the potential of dual GIP+GLP-1 receptor agonism in weight management. However, comparing percentage weight loss figures directly would be misleading due to different study protocols, patient populations, and endpoints. Your prescriber will consider individual factors such as your response to current treatment, side effect tolerance, and personal medical history when evaluating whether switching from Wegovy to Mounjaro may offer clinical advantages.
How Wegovy Works In Your Switch From Wegovy To Mounjaro Evaluation
Understanding how Wegovy currently works in your system helps inform discussions about switching from Wegovy to Mounjaro with your prescriber. Wegovy's semaglutide acts as a GLP-1 receptor agonist, mimicking the natural incretin hormone that signals fullness after eating. This mechanism reduces appetite by acting on brain appetite centres, promotes slower gastric emptying to enhance satiety, and may help reduce food cravings between meals. The once-weekly injection maintains consistent hormone levels, supporting appetite regulation when combined with lifestyle modifications.
Ordering Process For Switch From Wegovy To Mounjaro Through EverydayMeds
Transitioning from Wegovy to Mounjaro through EverydayMeds begins with our comprehensive 3-minute online clinical assessment, specifically designed to capture your current treatment history and reasons for considering a change. Our prescribers review your medical information within 3 working days (or 24 hours with express service), evaluating factors such as your current Wegovy dose, any side effects experienced, weight management progress, and overall health status. This thorough review ensures any switch from Wegovy to Mounjaro is clinically appropriate and safely managed with proper dose adjustment guidance. Once approved, your prescription is fulfilled through our temperature-controlled cold-chain delivery system, maintaining medication integrity from our GPhC-registered pharmacy (#9012878) directly to your door with next-day delivery.
Storage Differences When Planning Your Switch From Wegovy To Mounjaro
Storage requirements present a practical consideration when evaluating a switch from Wegovy to Mounjaro, particularly for patients who travel frequently or prefer treatment flexibility. Wegovy offers superior room temperature storage capability, remaining stable for up to 6 weeks when removed from refrigeration (below 30°C), compared to Mounjaro's 21-day room temperature limit. Both treatments require refrigeration at 2-8°C before first use and utilise pre-filled pen injection systems, though Wegovy's FlexTouch pen design differs from Mounjaro's KwikPen system. The dose escalation storage planning also differs, with Wegovy's 5-dose schedule requiring different refrigerator space management compared to Mounjaro's 6-dose progression over a longer timeframe.
Individual Response Factors In Switch From Wegovy To Mounjaro Decisions
Patient response variability represents a key factor driving switch from Wegovy to Mounjaro considerations, as individual tolerance and efficacy can differ significantly between treatments. Some patients may experience gastrointestinal side effects with semaglutide that could potentially be managed differently with tirzepatide's dual mechanism, though side effect profiles overlap substantially between GLP-1 based treatments. Weight management response, injection site tolerance, and lifestyle compatibility all influence whether switching treatments may offer advantages.
Your prescriber will evaluate multiple factors including your current weight management progress, side effect severity and management strategies, adherence to current dosing, and personal preferences regarding injection frequency and storage requirements. The decision to switch from Wegovy to Mounjaro should never be made independently, as both are prescription-only medicines requiring professional medical supervision throughout treatment transitions. EverydayMeds' clinical team provides ongoing support for patients considering treatment changes, ensuring continuity of care throughout your weight management journey.
Making Your Switch From Wegovy To Mounjaro Decision With Expert Support
Both Wegovy and Mounjaro are available from EverydayMeds, providing you with access to expert clinical guidance in determining which treatment may be most appropriate for your individual circumstances. Our experienced prescribers understand the nuances of switching between weight management treatments and can provide personalised advice based on your medical history, current treatment response, and weight management goals. Starting your clinical assessment takes just 3 minutes, with new customers benefiting from code FIRST40 and returning patients using code DOSE25 at checkout. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your confidential clinical assessment and explore both treatment options with professional medical guidance. Your weight management journey deserves expert support, and our GPhC-registered pharmacy team (#9012878) is here to help you make informed decisions about your prescription treatment options.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
